跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

GLAXOSMITHKLINE BIOLOGICALS

首页临床试验发起方与机构GLAXOSMITHKLINE BIOLOGICALS

GLAXOSMITHKLINE BIOLOGICALS

637 RUE DES AULNOIS, St Amand Les Eaux, Hauts De France, 法国

别名:

gsk biologicals - smithkline beecham biologicals

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

698

649 进行中

药物批准

57

批准总数

监管机构

4

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

295

42.3%

3 期

24

3.4%

不适用

15

2.1%

2 期

7

1.0%

4 期

5

0.7%

Unknown

1

0.1%

试验状态分布

进行中（未招募）

643

92.1%

已完成

20

2.9%

尚未招募

6

0.9%

招募中

27

3.9%

终止

1

0.1%

Unknown

1

0.1%

相关临床试验

该机构主办的试验（698）

A study on the immune response and safety of an investigational combined measles, mumps, rubella and varicella vaccine, when administered as intramuscular injection to healthy children 15 months to 6 years of age.

Oct 202665 名受试者

A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults

Jun 2026464 名受试者

Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 years and above.

May 20241650 名受试者

A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18-40 years or in participants aged 18-60 years with recurrent genital herpes.

进行中（未招募）

Apr 2024515 名受试者

A study on the safety, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide against chronic Hepatitis B (CHB) and chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.

Apr 2024205 名受试者

A study on the immune response, safety and the occurrence of RSV-associated respiratory tract illness after administration of RSV OA vaccine in adults 60 years and older.

Mar 20242600 名受试者

A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased risk for respiratory syncytial virus disease, compared to older adults 60 years of age and above.

进行中（未招募）

Mar 20241450 名受试者

Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infection.

Mar 2024115 名受试者

第 1 页，共 88 页

药物批准

按机构分类的批准

PHILIPPINES

Philippines FDA

1

药物批准

SFDA

Saudi Food and Drug Authority

6

药物批准

NPRA

National Pharmaceutical Regulatory Agency

2

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

48

药物批准

近期批准

SHINGRIX SUSPENSION INYECTABLE EN JERINGA PRECARGADA

INFANRIX-IPV VACCINE

ROTARIX ORAL SUSPENSION VACCINE

INFANRIX HEXA VACCINE

06 December 2024

资讯

暂无资讯文章

本页目录

概览
相关临床试验698
药物批准57
资讯

返回机构列表